N=~140
contact details, please visit
the J&J Clinical Trial Finder
Key eligibility criteria*:
- mCRPC with histologic confirmation of adenocarcinoma
- Measurable or evaluable disease
- PSA ≥2 ng/mL at screening
- Prior orchiectomy or medical castration; or receiving ongoing ADT with a GnRHa
- ECOG PS 0 or 1
- No symptomatic leptomeningeal disease or brain metastases
- No treatment with any anticancer or investigational agents within 14 days prior to the first study dose
- No prior KLK2-targeted therapy
- No prior PSMA-targeting therapy
- No prior ADCs with microtubule inhibitor payloads
- No T-cell redirecting treatment (eg, CD3-directed bispecific or CAR T-cell therapy) within 90 days prior to first study dose
Primary outcomes:
- DLTs
- AEs by severity
Secondary outcomes:
- ORR
- rPFS
- TTR
- PSA response rate
- DOR
- Serum concentration of pasritamig and JNJ-95298177
- ADAs
*Not a complete list of inclusion and exclusion criteria. †Dose de-escalation in accordance with BOIN.
Ab,
antibody; ADA, antidrug antibody; ADC, antibody-drug conjugate; ADT, androgen deprivation therapy; AE, adverse
event; BOIN, Bayesian optimal interval; CAR, chimeric antigen receptor; CD, cluster of differentiation; DLT,
dose-limiting toxicity; DOR, duration of response; ECOG PS, Eastern Cooperative Oncology Group performance status;
GnRHa, gonadotropin-releasing hormone analog; KLK2, human kallikrein-2; mCRPC, metastatic castration-resistant
prostate cancer; ORR, objective response rate; PSA, prostate-specific antigen; PSMA, prostate-specific membrane
antigen; rPFS, radiographic progression-free survival;TTR, time to response.